24
Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study
Sunday, March 29, 2015: 2:20 PM
International Ballroom (Hilton Chicago)
K. S. Tewari1, M. Sill2, B. J. Monk3, R. T. Penson4, H. Lankes2, M. M. Leitao5, L. M. Ramondetta6, L. Van Le7, D. L. Richardson8, L. M. Landrum9, P. A. DiSilvestro10, K. Behbakht11, F. R. Ueland12, H. Michael13 and M. J. Birrer14
1UC Irvine Medical Center, Orange, CA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Arizona Cancer Center, Phoenix, AZ, 4Massachusetts General Hospital/Harvard University, Boston, MA, 5Memorial Sloan Kettering Cancer Center, New York, NY, 6The University of Texas MD Anderson Cancer Center, Houston, TX, 7University of North Carolina at Chapel Hill, Chapel Hill, NC, 8University of Texas Southwestern Medical Center, Dallas, TX, 9The University of Oklahoma, Oklahoma City, OK, 10Women and Infants Hospital, Brown University, Providence, RI, 11University of Colorado Denver, Aurora, CO, 12University of Kentucky Medical Center, Lexington, KY, 13Indiana University School of Medicine, Indianapolis, IN, 14Massachusetts General Hospital Cancer Center/Harvard University, Boston, MA
